We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
At times a biomedical, pharma, or a medical company has one very strong drug or product that enables the company to research and develop other new drugs while their primary drug is bringing in the necessary revenues. But when your big drug starts to see a significant decline in expected sales, no matter how good your pipeline is, it begins to negatively impact other parts of the business. This issue is compounded if operating and R&D expenses increase at the same time. These are the issues facing our Zacks Bear of the Day, Seattle Genetics .
SGEN, a Zacks Ranked #5 (Strong Sell), is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials.
Recent Earnings Data
On February 9th, SGEN announced earnings where they missed both the Zacks consensus earnings and revenue estimates. During the announcement management stated that their primary drug ADCETRIS’s annual sales would only show 9% annual sales growth in FY 17, half of what was achieved in 2016, and well below the previously expected 30% annual sales growth. Further, it was learned that one of their other key growth drivers CTCL will not get in the product label until 2018. This news caused analysts to cut their estimates through FY 2018.
Management’s Take
According to Clay Siegall, Ph.D., President and Chief Executive Officer, “Our accomplishments in 2016 were substantial, highlighted by strong progress with our ADCETRIS phase 3 trials: ALCANZA, ECHELON-1 and ECHELON-2. This progress positions us to potentially achieve a series of regulatory and commercial milestones in 2017 and 2018. Also during 2016 we initiated the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A; 33A) and reported phase 1 data from enfortumab vedotin (ASG-22ME) that we believe support advancement of this program into registrational trials. As we evolve into a global, multi-product oncology company, we are focused on continuing to deliver on our goals of advancing our pipeline and establishing ADCs as a key component of the future of cancer care.”
Price and Earnings Consensus Graph
As you can see below, due to reduced sales guidance, we get a kind of odd graph; the stock price is up, but analyst’s expectations have decreased significantly.
Due to the reduced sales guidance, and increased operating and R&D expenses estimates for Q1 17, Q2 17, FY 17, and FY 18 have all see negative revisions over the past 30 days; Q1 17 fell from -$0.27 to -$0.42, Q2 17 dropped from -$0.27 to -$0.45, FY 17 slipped from -$0.89 to -$1.55, and FY 17 plummeted from -$0.18 to -$1.27.
Bottom Line
While the company has a nice pipeline of drugs, the big decline in revenues from their main drug ADCETRIS®, and increase in overall expenses has us on the sidelines with this stock until FY 2018 when CTCL gets its product label.
If you are inclined to invest in the Biomedical and Genetic sector, you would be best served by looking into Cellectis S.A. (CLLS - Free Report) , and or Momenta Pharma , both of which currently carry a Zacks Rank #1 (Strong Buy).
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bear of the Day: Seattle Genetics (SGEN)
At times a biomedical, pharma, or a medical company has one very strong drug or product that enables the company to research and develop other new drugs while their primary drug is bringing in the necessary revenues. But when your big drug starts to see a significant decline in expected sales, no matter how good your pipeline is, it begins to negatively impact other parts of the business. This issue is compounded if operating and R&D expenses increase at the same time. These are the issues facing our Zacks Bear of the Day, Seattle Genetics .
SGEN, a Zacks Ranked #5 (Strong Sell), is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials.
Recent Earnings Data
On February 9th, SGEN announced earnings where they missed both the Zacks consensus earnings and revenue estimates. During the announcement management stated that their primary drug ADCETRIS’s annual sales would only show 9% annual sales growth in FY 17, half of what was achieved in 2016, and well below the previously expected 30% annual sales growth. Further, it was learned that one of their other key growth drivers CTCL will not get in the product label until 2018. This news caused analysts to cut their estimates through FY 2018.
Management’s Take
According to Clay Siegall, Ph.D., President and Chief Executive Officer, “Our accomplishments in 2016 were substantial, highlighted by strong progress with our ADCETRIS phase 3 trials: ALCANZA, ECHELON-1 and ECHELON-2. This progress positions us to potentially achieve a series of regulatory and commercial milestones in 2017 and 2018. Also during 2016 we initiated the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A; 33A) and reported phase 1 data from enfortumab vedotin (ASG-22ME) that we believe support advancement of this program into registrational trials. As we evolve into a global, multi-product oncology company, we are focused on continuing to deliver on our goals of advancing our pipeline and establishing ADCs as a key component of the future of cancer care.”
Price and Earnings Consensus Graph
As you can see below, due to reduced sales guidance, we get a kind of odd graph; the stock price is up, but analyst’s expectations have decreased significantly.
Seattle Genetics, Inc. Price and Consensus
Seattle Genetics, Inc. Price and Consensus | Seattle Genetics, Inc. Quote
Declining Estimates
Due to the reduced sales guidance, and increased operating and R&D expenses estimates for Q1 17, Q2 17, FY 17, and FY 18 have all see negative revisions over the past 30 days; Q1 17 fell from -$0.27 to -$0.42, Q2 17 dropped from -$0.27 to -$0.45, FY 17 slipped from -$0.89 to -$1.55, and FY 17 plummeted from -$0.18 to -$1.27.
Bottom Line
While the company has a nice pipeline of drugs, the big decline in revenues from their main drug ADCETRIS®, and increase in overall expenses has us on the sidelines with this stock until FY 2018 when CTCL gets its product label.
If you are inclined to invest in the Biomedical and Genetic sector, you would be best served by looking into Cellectis S.A. (CLLS - Free Report) , and or Momenta Pharma , both of which currently carry a Zacks Rank #1 (Strong Buy).
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>